PharmaGap Inc.

TSX VENTURE: GAP
OTC Bulletin Board: PHRGF

OTTAWA, ONTARIO--(Marketwire - Aug. 13, 2009) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") has been advised by the U.S. National Cancer Institute ("NCI") that the Company's lead cancer drug GAP-107B8 (formerly known as PhG-alpha-1) has demonstrated sufficient anti-proliferative effect in the NCI's initial single dose assay to warrant examination in an expanded "dose response" assay in which the compound will be evaluated against the NCI-60 cancer cell panel at five concentration levels. The NCI has further advised that the threshold for progression to the dose response assay is based on results in the single dose assay in comparison with historical data of compounds screened by the NCI that were of sufficient interest for review by the NCI's DTP Biological Evaluation Committee. The NCI-60 protocol tests a wide variety of cancers, including breast, colorectal, lung, ovarian, kidney, prostate, leukemia and various central nervous system cancers and melanomas. A complete outline of the NCI's compound screening process can be found at http://dtp.cancer.gov/screening.html.

The Company has not yet received the data from the single line screen for analysis, and accordingly cannot provide further comment until such data is received and analyzed. The Company will announce the full results and interpretation of data following receipt of data from the NCI.

The Company provides this update in advance of receipt of full test data in order to ensure full compliance with the Company's continuous disclosure obligations, in light of recent market activity in the Company's shares.

About The National Cancer Institute

The National Cancer Institute ("NCI") is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI's mandate is to conduct and foster cancer research in the United States, and is located in Bethesda, Maryland. For more information please visit www.cancer.gov.

About PharmaGap Inc.

PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C ("PKC"), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com.

Note: No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.